 The European Commission has approved Horizon Therapeutics plcs NASDAQ: HZNP Uplizna inebilizumab as monotherapy for neuromyelitis optica spectrum disorder NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive AQP4-IgG. NMOSD is an autoimmune disease that attacks. 